By Journal Staff
In an era where medical advancement is often measured in incremental steps, the leadership of METAvivor Research and Support is pushing for a giant leap. In her latest correspondence to stakeholders, Dr. Kelly Shanahan, President of the organization and a prominent voice in the metastatic breast cancer (MBC) community, detailed a landscape of both immense opportunity and sobering fiscal reality. As the organization moves into the 2026 grant cycle, it faces a record-breaking influx of research proposals, a shifting economic environment, and the personal, tireless struggle of those living with the very disease they seek to cure.
Main Facts: A Record-Breaking Call for Innovation
The primary focus of Dr. Shanahan’s address is the unprecedented interest in the organization’s 2026 grant cycle. METAvivor, which distinguishes itself by directing 100% of its donations toward research for metastatic (Stage IV) breast cancer, has reported a record number of Letters of Intent (LoIs) from the global scientific community.
Of these submissions, approximately 75% are directed toward the organization’s flagship "translational award" mechanism. These grants, valued at $450,000 each, represent a significant investment in research designed to move discoveries from the laboratory bench to the patient’s bedside. The surge in applications highlights a growing recognition within the scientific community that metastatic disease—the only form of breast cancer that kills—requires specialized, targeted funding that traditional grant structures may overlook.
To meet this demand, Dr. Shanahan has set a fundraising target of $3.75 million for the current year. While she characterized this goal as "realistic" compared to past "lofty" aspirations, it remains a formidable task given the current global economic uncertainty. The funds are earmarked not just for the grants themselves, but to sustain the rigorous review process that ensures only the most promising science receives backing.
Chronology: The Relentless Pace of Advocacy and Treatment
The timeline of the current grant cycle is framed by the personal journey of Dr. Shanahan herself, who embodies the dual role of a medical professional and a patient participating in a clinical trial. Over the past eight weeks, the organization’s leadership has operated at a fever pitch, balancing administrative oversight with the grueling realities of living with MBC.
- Late Summer/Early Autumn 2024: The call for Letters of Intent (LoIs) for the 2026 cycle was issued, resulting in a historic volume of responses.
- The Past 60 Days: Dr. Shanahan has maintained a rigorous travel schedule, including 1,100-mile trips for clinical trial participation. This period also included high-level advocacy events and scientific conferences, punctuated by brief moments of personal respite.
- The Current Phase: The organization is currently in the "midst of reviewing" these LoIs. This is a critical juncture where the massive pool of applicants is narrowed down to those invited to submit full proposals.
- The Year Ahead: Fundraising efforts are intensifying to meet the $3.75 million threshold before the 2026 grants are officially awarded.
This chronology underscores a sense of urgency. For the metastatic community, the timeline of a grant cycle is not merely an administrative calendar; it is a race against time.
Supporting Data: The Economics of Translational Research
The data provided by Dr. Shanahan paints a picture of a research community hungry for resources. The fact that three-quarters of applicants are vying for the $450,000 translational awards is statistically significant.
The Importance of Translational Awards
Translational research is the "connective tissue" of modern medicine. While basic research seeks to understand the fundamental mechanics of a disease, and clinical trials test specific drugs on humans, translational research bridges the two. In the context of MBC, this might involve:
- Developing new biomarkers to predict which patients will respond to immunotherapy.
- Identifying mechanisms of drug resistance in real-time.
- Adapting existing treatments for other cancers to work specifically on breast cancer metastases in the brain or bones.
The $450,000 price tag per award is calculated to provide substantial runway for multi-year projects, allowing researchers to hire staff, purchase specialized equipment, and conduct the high-level data analysis required for breakthroughs.
The $3.75 Million Fundraising Mandate
The decision to set the annual goal at $3.75 million reflects a strategic pivot. In previous years, non-profits in the oncology space have seen fluctuations in donor behavior linked to inflation and market volatility. By setting a "realistic" goal, METAvivor aims to ensure that every promise made to a researcher can be kept.
Dr. Shanahan’s appeal for "micro-donations"—framed as "giving up a fancy coffee"—is a data-driven fundraising strategy. While large-scale corporate sponsorships are vital, the "grassroots" model of small, recurring donations provides a more stable and resilient financial base for non-profits during periods of economic "uncertainty."
Official Responses: The Philosophy of Peer Review
Central to Dr. Shanahan’s message is the unique "dual-review" system employed by the organization. Unlike many traditional funding bodies that rely solely on a panel of academic scientists, METAvivor utilizes both scientific reviewers and patient advocate reviewers.
"We cannot do this without both scientific reviewers and patient advocate reviewers," Dr. Shanahan stated. This approach ensures that the research is not only scientifically sound but also "patient-centric."
The Role of Scientific Reviewers
These experts assess the technical feasibility of the proposals. They look at the methodology, the statistical power of the study, and the novelty of the hypothesis. Their role is to ensure that the $450,000 investment is going toward high-quality, reproducible science.
The Role of Patient Advocate Reviewers
Patient advocates—often those living with MBC themselves—provide a different lens. They evaluate the "clinical impact" and the "burden" of the proposed research. They ask:
- Will this research lead to a better quality of life?
- Is the proposed treatment schedule realistic for someone living with a terminal illness?
- Does this address a gap in care that patients are actually experiencing?
This collaborative review process has become a gold standard in the advocacy world, ensuring that the "ivory tower" of academia remains connected to the "living room" of the patient.
Implications: The Future of Metastatic Breast Cancer Funding
The implications of Dr. Shanahan’s update are twofold: one for the scientific community and one for the donor public.
For the Scientific Community
The record number of LoIs suggests a "bottleneck" in federal funding. If researchers are turning to private organizations like METAvivor in record numbers, it indicates that the National Institutes of Health (NIH) and other major bodies may not be providing enough dedicated funding for metastatic research. Historically, only about 7% of breast cancer research funding is directed toward metastatic disease, despite it being responsible for nearly all breast cancer deaths. METAvivor’s growth is a direct response to this disparity.
For the General Public and Donors
Dr. Shanahan’s letter serves as a call to action that shifts the narrative of breast cancer awareness. By focusing on the "1,100 miles" she travels for a trial and the "record number" of researchers waiting for funding, she highlights that the "pink ribbon" month of October is only a small part of a much larger, 365-day struggle.
The move toward a $3.75 million goal signifies a maturing organization that is prioritizing sustainability over pure growth. However, the reliance on individual contributions ("giving up a fancy coffee") highlights the precarious nature of non-profit medical research. If the goal is not met, the implication is clear: some of those record-breaking, potentially life-saving translational projects will go unfunded.
Conclusion: A Call for Collective Action
Dr. Kelly Shanahan’s "Letter from the President" is more than a status update; it is a dispatch from the front lines of a war on a disease that claims over 42,000 lives annually in the United States alone. The airport setting of her letter—symbolizing the constant movement, the fatigue, and the distance traveled—serves as a poignant metaphor for the state of metastatic research.
As the 2026 grant cycle progresses, the eyes of the oncology world will be on the $3.75 million target. The success of this fundraising effort will determine how many of those $450,000 translational awards can be granted, and by extension, how many new pathways to survival can be opened for patients who have run out of standard options. In the words of Dr. Shanahan, "Every little bit counts," and in the world of metastatic research, those "little bits" are the building blocks of a future where Stage IV is no longer a death sentence.
About the Author
